It was first approved in China in January 2026 for blood sugar control in adults with type 2 diabetes, and in March 2026 for long-term weight management.1 In its 40-week phase 3 weight trial, adults lost 13.2% of their weight on the 2.4 mg dose, while weight on placebo rose by 0.1%.2 We found no label for it on DailyMed, the U.S. database of drug labels, on November 20, 2026.3
What it is
Ecnoglutide is a peptide modeled on GLP-1, like semaglutide. Its developers swapped one amino acid near the start of the chain and attached an 18-carbon fatty acid, the same kind of tail that makes semaglutide last a week. In an early trial its half-life at steady state was 124 to 138 hours, which supports weekly dosing.4
What its makers stress is a property called signaling bias. In laboratory tests ecnoglutide strongly triggered the receptor's main internal signal, a molecule called cyclic AMP, but barely caused the receptor to be pulled into the cell, which normally happens after it is activated. The developers describe this as a desirable bias, and their review of approvals calls it a cAMP-biased GLP-1 receptor agonist.1,4 Whether that bias gives people better results than other GLP-1 medicines is not shown by the trials described here.
The early work had three other findings. In rats and mice, ecnoglutide lowered blood sugar and led to more weight loss than semaglutide. In its first human trial, weekly injections for up to 6 weeks were generally safe and well tolerated. And the developers report that it is simpler to manufacture.4 The comparison with semaglutide was made in animals only; the phase 3 trial below shows what happened in people, and it did not include semaglutide.
The phase 3 weight trial
The trial enrolled 664 adults without diabetes at 36 centers in China. They qualified with a body mass index of at least 28, or at least 24 with a weight-related condition such as prediabetes, high blood pressure, high cholesterol, fatty liver disease, sleep apnea or joint pain. They took ecnoglutide 1.2 mg, 1.8 mg or 2.4 mg, or placebo, once a week.2
- At week 40, weight fell by 9.1%, 10.9% and 13.2% on the three doses, while it rose by 0.1% on placebo.
- A loss of at least 5% was reached by 77%, 84% and 87%, against 16% on placebo.
- Adverse events of any kind were reported by 93% in each ecnoglutide group and 84% on placebo.
The trial was funded by Hangzhou Sciwind Biosciences, the developer.2
Side effects
In the early trial, the adverse events included decreased appetite, nausea and headache, the familiar pattern of the GLP-1 class.4 Our page on nausea on a GLP-1 covers what helps.
Next to the approved U.S. medicines
The phase 3 trial was shorter than the U.S. label trials, 40 weeks against 68 for Wegovy and 72 for Zepbound, and it enrolled Chinese adults under lower body mass index thresholds than the 30, or 27 with a condition, used in those trials.2,5 Wegovy 2.4 mg lowered weight by 14.9% in its own trial.5 Side-by-side numbers from such different trials are a rough guide only.
What comes next
The 2026 review of its approvals lists trials under way in teenagers with obesity, and in adults with obesity and sleep apnea or knee osteoarthritis, and notes that a tablet form is in development.1 Without a U.S. label, ecnoglutide is not available as a prescription medicine in the United States.3
Sources
- Shirley M. Ecnoglutide: first approvals. Drugs 2026;86:1563-1570. doi:10.1007/s40265-026-02350-w
- Ji L, Gao L, Xue H, et al. Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 2025;13:777-789. Funded by Hangzhou Sciwind Biosciences. doi:10.1016/S2213-8587(25)00141-X
- DailyMed, U.S. National Library of Medicine. Search for "ecnoglutide", no results; read November 20, 2026. dailymed.nlm.nih.gov
- Guo W, Xu Z, Zou H, et al. Discovery of ecnoglutide: a novel, long-acting, cAMP-biased glucagon-like peptide-1 (GLP-1) analog. Mol Metab 2023;75:101762. doi:10.1016/j.molmet.2023.101762
- WEGOVY (semaglutide) prescribing information, NDA 215256/S-025, revised June 2026, section 14; and ZEPBOUND (tirzepatide) prescribing information, NDA 217806/S-041, revised August 2026, section 14. U.S. Food and Drug Administration. accessdata.fda.gov
Related analyses
Ozempic vs Wegovy: the same drug under two labels, compared by dose, results and price
Nausea on a GLP-1: how common, how long, when it peaks and what helps
Wegovy weight loss chart: the trial results week by week, in your own weight
GLP-1 cost without insurance: every manufacturer self-pay price, dose by dose
Log any GLP-1 medicine you take and see your doses, weight and symptoms together.
Open Dose Insider